OncoTherapy Science AI Stock Analysis
Want to see JP:4564 full AI Analyst Report?
OncoTherapy Science (4564) AI Stock Analysis
OncoTherapy Science
(TSE/TYO:4564)
The score is driven primarily by severely weak financials: chronic unprofitability, losses larger than revenue, negative gross margins, and roughly ¥1B of annual cash burn that forces reliance on dilutive capital raises. A debt-free balance sheet is the only meaningful financial positive. Technicals reinforce the caution, with the price below all major moving averages and a negative MACD, though an oversold stochastic hints at possible short-term stabilization. Valuation adds no support given a negative P/E and no dividend. This remains a high-risk, speculative biotech whose outcome hinges on pipeline success and continued access to funding.
OncoTherapy Science (4564) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.12B
- Dividend Yield
- ―
- Average Volume (3M)
- 182.35M
- Price to Earnings (P/E)
- -6.5
- Beta (1Y)
- 1.02
- Revenue Growth
- -25.56%
- EPS Growth
- 17.01%
- Country
- Japan
- Employees
- 46
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
OncoTherapy Science Business Overview & Revenue Model
Company Description
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound th...
OncoTherapy Science Financial Statement Overview
Summary
Financials are very weak. The company is persistently unprofitable, with net losses exceeding revenue (FY2026 forecast: ¥911M loss on ¥809M of revenue) and negative gross and EBIT margins (Income Statement score 10). Cash flow is the biggest concern, with operating and free cash flow deeply negative every year and roughly ¥1B of annual cash burn projected for FY2026 (Cash Flow score 8). The balance sheet is the relative bright spot — minimal to zero debt — but equity has been eroded by losses and only rebuilt through capital raises that dilute shareholders, with deeply negative returns on equity (Balance Sheet score 35). Survival depends on continued external financing and pipeline success.
Income Statement
10Very NegativeBalance Sheet
35NegativeCash Flow
8Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 749.75M | 808.53M | 750.05M | 610.12M | 1.13B | 332.48M |
| Gross Profit | -12.76M | 13.96M | -12.76M | -177.72M | 41.69M | 19.54M |
| EBITDA | -126.67M | -810.38M | -14.92M | -165.50M | -1.10B | -1.59B |
| Net Income | -815.05M | -910.64M | -815.28M | -1.29B | -1.12B | -1.56B |
Balance Sheet | ||||||
| Total Assets | 1.16B | 2.36B | 1.16B | 867.27M | 1.51B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 833.88M | 2.09B | 833.88M | 527.66M | 1.12B | 2.90B |
| Total Debt | 51.07M | 0 | 51.07M | 106.85M | 0 | 0 |
| Total Liabilities | 426.09M | 217.37M | 426.09M | 513.61M | 656.27M | 291.28M |
| Stockholders Equity | 729.11M | 2.14B | 729.11M | 353.67M | 855.17M | 3.08B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -984.97M | -815.30M | -1.23B | -800.29M | -1.81B |
| Operating Cash Flow | 0 | -922.75M | -815.02M | -1.23B | -794.90M | -1.76B |
| Investing Cash Flow | 0 | -63.22M | -279.00K | -33.35M | -20.32M | -52.23M |
| Financing Cash Flow | 0 | 2.24B | 1.12B | 671.37M | 95.95M | 0 |
OncoTherapy Science Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Negative. The current price of 15.00 is below the 20-day moving average (MA) of 16.65, below the 50-day MA of 19.00, and below the 200-day MA of 20.64, indicating a bearish trend. The MACD of -1.03 indicates Positive momentum. The RSI at 30.84 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4564.
OncoTherapy Science Peers Comparison
Overall Rating
JP:456563Neutral
JP:457962.4Neutral
JP:458851Neutral
JP:458748Neutral
JP:457141Neutral
JP:456426Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | JPY 154.11B | -26.91 | -8.51% | ― | 23.72% | 12.48% | |
| 62Neutral | JPY 18.95B | 42.63 | ― | ― | 31.84% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | JPY 208.84B | -122.94 | ― | ― | 1748.97% | 35.11% | |
| 48Neutral | JPY 144.11B | -48.17 | -5.85% | ― | 14.25% | 50.07% | |
| 41Neutral | JPY 6.37B | -4.20 | -39.57% | ― | 48.92% | -46.91% | |
| 26Underperform | JPY 6.12B | -6.52 | -42.81% | ― | -25.56% | 17.01% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4564 | OncoTherapy Science, Inc. | 15.00 | -6.00 | -28.57% | |
| JP:4587 | Peptidream | 1110.00 | -516.00 | -31.73% | |
| JP:4565 | Sosei Group Corporation | 1664.00 | 802.00 | 93.04% | |
| JP:4571 | NanoCarrier Co., Ltd. | 70.00 | -74.00 | -51.39% | |
| JP:4579 | RaQualia Pharma Inc. | 728.00 | 39.00 | 5.66% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7070.00 | 6105.00 | 632.64% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
